You are viewing the site in preview mode
Skip to main content
|
1
|
Assessment at baseline just before and response at 1–2 weeks after end of chemotherapy cycle
|
|
2
|
Progressive disease (PMD) FDG SUV >25% within tumour RO1 of baseline
|
|
3
|
Stable disease (SMD) FDG SUV <25% ≥15%
|
|
4
|
Partial response (PMR) FDG SUV decrease of 15–25% after one cycle of chemotherapy or decrease over 25% for more than one cycle
|
|
5
|
Complete response (CMR) FDG SUV shows complete resolution within the baseline tumour RO1
|
|
6
|
Patlak kinetic approach is preferred. Reproducibility of FDG SUV is required.
|
- FDG, 18F Fluorodeoxyglucose; SUV, Standard Uptake Value.
